Great Plains Health Systems Investigate Treatment Options for COVID-19 Patients: Ivermectin Study Planned

Great Plains Health Systems Investigate Treatment Options for COVID-19 Patients Ivermectin Study Planned

Sanford Health and Essentia Health exemplify rock solid American Midwestern-Great Plains health systems on the front lines of the COVID-19 pandemic. Both health systems have embraced investigational therapies to treat a previously unknown, novel coronavirus as clinical investigators have scrambled for proven treatments to deal with an unprecedented modern-era health crisis. From Actemra and remdesivir to stem cell therapy and even the antiparasitic drug ivermectin—embraced in South America and parts of Asia—Great Plains’ health professionals work around the clock to help patients fight off this new and at times deadly pathogen.

Recently Duluth News Tribune’s Patrick Springer wrote a good summary of how researchers at Great Plains providers, such as Sanford Health and Essentia Health, scramble to find treatments that can help their patients beat SARS-CoV-2, the virus behind the COVID-19 pandemic.

TrialSite News offers a summary of the experimentation ongoing by researchers within prominent health systems across America, and the world.


Known as tocilizumab and atlizumab, the immunosuppressive drug called Actemra used mainly for rheumatoid arthritis (RA) and ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee